Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a cash flow conversion efficiency ratio of -1.158x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-149.92 Million) by net assets ($129.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biohaven Pharmaceutical Holding Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Biohaven Pharmaceutical Holding Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore long-term investment intensity of Biohaven Pharmaceutical Holding Co Ltd to see how much of total assets are deployed in long-term investments.
Biohaven Pharmaceutical Holding Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohaven Pharmaceutical Holding Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gunkul Engineering Public Company Limited
BK:GUNKUL
|
0.062x |
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
0.009x |
|
Luolai Home Textile Co Ltd
SHE:002293
|
0.040x |
|
Alkane Resources Ltd
AU:ALK
|
0.156x |
|
Crombie Real Estate Investment Trust
TO:CRR-UN
|
0.041x |
|
Taiji Computer Corp Ltd
SHE:002368
|
0.046x |
|
Peoples Bancorp Inc
NASDAQ:PEBO
|
0.028x |
|
Gansu Jiu Steel Group Hongxing Iron & Steel Co Ltd
SHG:600307
|
0.130x |
Annual Cash Flow Conversion Efficiency for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see BHVN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.07 Million | $-609.44 Million | -11.704x | -750.85% |
| 2024-12-31 | $423.44 Million | $-582.45 Million | -1.376x | -77.47% |
| 2023-12-31 | $427.98 Million | $-331.73 Million | -0.775x | -40.28% |
| 2022-12-31 | $538.77 Million | $-297.69 Million | -0.553x | +64.13% |
| 2021-12-31 | $94.69 Million | $-145.84 Million | -1.540x | -55.69% |
| 2020-12-31 | $76.78 Million | $-75.96 Million | -0.989x | -101.95% |
| 2019-12-31 | $-7.42 Million | $-377.33 Million | 50.826x | +3990.94% |
| 2018-12-31 | $150.92 Million | $-197.14 Million | -1.306x | -81.82% |
| 2017-12-31 | $131.97 Million | $-94.81 Million | -0.718x | -- |
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more